Australia TGA Updates Guidance on AI-Enabled Medical Device Software and ARTG Evidence Requirements

Details of the Update

The updated guidance clarifies that AI-enabled software is regulated as a medical device based on its intended purpose, regardless of the underlying technology or delivery platform. Software intended for diagnosis, monitoring, or treatment must be included in the Australian Register of Therapeutic Goods (ARTG) before it can be supplied in Australia.

The guidance explains manufacturers’ obligations to manage software updates and scope creep, emphasizing that changes which alter intended use or performance may trigger the need for regulatory approval prior to release. It also addresses off-label use, stating that when such use is detected, manufacturers are required to either restrict it or seek ARTG inclusion for the new indication.

In relation to evidence generation, the TGA clarifies expectations for synthetic data, noting that while it may be used to supplement clinical evidence, it cannot replace real-world clinical data. Where synthetic data is used for validation, manufacturers must document both the rationale for its use and the methods used to generate it. 

Effective Date

The updated TGA guidance on AI-enabled medical device software applies from February 5, 2026.

Why It Matters

This update provides greater regulatory clarity on how AI-driven medical device software is assessed, maintained, and evidenced across its lifecycle. By setting clearer expectations around digital health technologies, update management, and evidence standards, the guidance supports more consistent regulatory alignment while aiming to reduce uncertainty and unnecessary compliance burden for regulated stakeholders.

Who This Is Relevant For

The guidance is relevant for regulatory affairs, quality assurance, patient safety, legal and compliance, commercial and marketing, and R&D teams involved in the development and lifecycle management of AI-based medical device software in Australia.

Next Steps

Organizations should review current and pipeline AI-enabled software products to confirm alignment with the clarified ARTG inclusion criteria and documentation expectations. Internal processes for managing software updates and off-label use detection should be assessed to ensure they meet the updated guidance, and evidence strategies should be reviewed where synthetic data is used in validation.

As regulatory expectations for AI-driven medical devices continue to evolve, staying ahead of guidance updates is critical. RegASK is a leading agentic AI regulatory intelligence and workflow orchestration platform that empowers global organizations in highly regulated sectors, including consumer products and life sciences, to proactively navigate complex regulatory landscapes. By combining advanced Agentic AI with experts in the loop, RegASK delivers timely predictive actionable insights and end-to-end automation, streamlining compliance processes, mitigating risks, and accelerating market access across more than 160 countries. Learn more or book a demo now. 

FAQs

When is AI-enabled software regulated as a medical device in Australia?

AI-enabled software is regulated as a medical device when its intended purpose is for diagnosis, monitoring, or treatment, regardless of the technology or platform used.

Is ARTG inclusion required for AI-based medical device software?

Yes. AI-enabled software intended for diagnosis, monitoring, or treatment must be included in the ARTG before supply in Australia.

Can synthetic data replace clinical evidence under the updated guidance?

No. Synthetic data may supplement but not replace clinical evidence, and its use must be justified and documented.

How can RegASK support teams managing AI medical device compliance?

RegASK helps organizations track regulatory updates like this TGA guidance, assess impact across product portfolios, and coordinate compliant responses using AI-driven insights combined with expert regulatory oversight.